Marine-based enzymatic treatment for severe wound debridement
Wound healing
LCE from trout • Enzymatic debridement• Novel drug
Phase 1
Phase 2
Phase 3
WoundClear™ is a novel, marine-based enzymatic drug, intended to aid in debridement of severe wounds.
  • Partial and full-thickness wounds with eschar development, in conjunction with or as stand-alone debridement therapy
  • Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
  • Pressure ulcers
  • Chronic vascular ulcers
  • Diabetic ulcers
WoundClear™ utilizes the LCE1 fusion protein from trout to facilitate debridement of eschar (necrotic tissue) in severe wounds. It is currently in the discovery stage.

WoundClear™ development is led by Regenics, and supported by researchers at RISE AB (Sweden).
WoundClear™ is intended to support treatment of:
A quick summary of WoundClear™
Natural ingredients
A novel marine-based treatment for severe wound debridement.
LCE from trout
Severe wound debridement
Collex® is an advanced wound dressing containing HTX™, designed to aid healing of partial thickness burns and chronic wounds.
Vernex® is an HTX™-based hydrogel wound spray, intended for treatment of partial thickness burns and chronic wounds.
Other products